Hird Nick, Ghosh Samik, Kitano Hiroaki
Takeda Pharmaceutical Company Limited, Fujisawa 251-8555, Japan.
The Systems Biology Institute, Tokyo 108-0071, Japan.
Drug Discov Today. 2016 Jun;21(6):900-11. doi: 10.1016/j.drudis.2016.01.010. Epub 2016 Jan 25.
The convergence of technology and medicine has pushed healthcare to the brink of a major disruption that pharma has, until recently, been slow to recognize. Tech players have pioneered the emerging field of digital wellness and health, and pharma is ideally placed to use its expertise in drug development and embrace these technologies to create digital applications that address major medical needs. This review describes digital innovation from a pharma R&D perspective, outlining principal drivers, digital components, opportunities and challenges as well as a sustainable new business model predicated on empowered patients and achieving therapeutic outcomes.
技术与医学的融合已将医疗保健推向重大变革的边缘,而制药行业直到最近才迟迟认识到这一点。科技企业已率先进入数字健康这一新兴领域,制药行业在利用其药物研发专业知识并采用这些技术来创建满足重大医疗需求的数字应用方面具有得天独厚的条件。本综述从制药研发的角度描述了数字创新,概述了主要驱动因素、数字组件、机遇与挑战,以及基于赋能患者和实现治疗效果的可持续新商业模式。